What is a phase III antibiotic worth?8 Jun 2021 00:16
In 2014, Paratek went public in a manoeuvre called a reverse merger, folding itself into a US company named Transcept Pharmaceuticals that was already listed on the NASDAQ stock exchange, but which had seen disappointing sales and was running with a skeleton crew. The deal earned Paratek $110 million, enabling it to launch omadacycline’s phase III trials and begin a careful restaffing programme. In October 2018, the FDA approved the drug in oral and intravenous formulations against two conditions: complicated skin infections and community-acquired bacterial pneumonia.
Just an example of what might have been with a good bod. Unfortunately we had crooks and idiots
In charge.
GS